Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Herthena-Lung02 data are an ASCO shocker.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
